共 50 条
- [3] Re: Logan G. Briggs, Chanan Reitblat, Paul A. Bain, et al. Prehabilitation Exercise Before Urologic Cancer Surgery: A Systematic and Interdisciplinary Review. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.05.015 Strategies for Effective Prehabilitation in Urologic Cancer [J]. EUROPEAN UROLOGY, 2021, 80 (06) : E139 - E140
- [5] Re: Sanoj Punnen, Matthew R. Cooperberg, Anthony V. D'Amico, et al. Management of Biochemical Recurrence After Primary Treatment of Prostate Cancer: A Systematic Review of the Literature. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2013.05.025 [J]. EUROPEAN UROLOGY, 2013, 64 (05) : E102 - E102
- [6] Re: R. Jeffrey Karnes, Voleak Choeurng, Ashley E. Ross, et al. Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. Eur Urol. In press. https://doi.org/10.1016/j.eururo. 2017.03.036 [J]. EUROPEAN UROLOGY, 2017, 72 (06) : E157 - E157
- [8] Re: Simpa S. Salami, Jeffrey J. Tosoian, Srinivas Nallandhighal, et al. Serial Molecular Profiling of Low-grade Prostate Cancer to Assess Tumor Upgrading: A Longitudinal Cohort Study. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.06.041 [J]. EUROPEAN UROLOGY, 2021, 79 (03) : E98 - E99
- [9] Re: Michael Baboudjian, Romain Diamand, Alessandro Uleri, et al. Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate Cancer Lead to Overtreatment? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.02.003 [J]. EUROPEAN UROLOGY, 2024, 86 (03) : e71 - e71
- [10] Re: Russell EN Becker, Alexa R. Meyer, Aaron Brant, et al. Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.016 [J]. EUROPEAN UROLOGY, 2021, 79 (02) : E56 - E57